Medical Device Packaging Market: as AptarGroup folds Invetech's connectivity and smart packaging division into its portfolio while Amcor and Berry Global work toward closing the largest healthcare packaging combination in years, the industry's two biggest strategic bets, digital-enabled packaging and sheer manufacturing scale, are being placed simultaneously by different companies, so device OEMs choosing a packaging partner increasingly need to decide which bet matters more for their own product roadmap, connected packaging intelligence or the negotiating leverage and reliability of a combined USD 24 billion supplier.

The global medical device packaging market size was USD 11.80 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as sterile barrier system demand tied to sustained global device production volume, manufacturer consolidation combining plastics and packaging capacity at a scale not previously seen in this market, and smart packaging technology extending connectivity and traceability into biologic and combination product packaging. The first driving factor is sterile barrier system demand, which tracks the underlying global medical device production volume that every sterile, single-use device requires validated packaging to reach patients safely. Flexible packaging accounts for the largest single format category share, reflecting pouches, lidding films, and sterile barrier bags' centrality to the majority of sterile device packaging applications. The second driving factor is manufacturer consolidation combining plastics and packaging capacity, as the largest packaging companies pursue transactions that reshape the competitive landscape at a scale not previously seen in this market. The third driving factor is smart packaging technology extending connectivity and traceability capability into biologic and drug-device combination product packaging. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single packaging manufacturer's acquisition of a smart packaging or connectivity specialist converts a conventional materials and format supplier into a broader digital-enabled packaging platform, which lets that manufacturer capture a device OEM's packaging specification for biologic and combination products that increasingly require connected features alongside sterile barrier performance. Because an increasing share of new biologic and drug-device combination products specify packaging that supports connectivity features such as usage tracking or cold-chain monitoring alongside traditional sterile barrier requirements, a packaging manufacturer that acquires connectivity and smart packaging technology directly expands its addressable specification opportunity into this higher-value, faster-growing product category without requiring an entirely new internal technology development programme. As a result, demand and revenue share in the smart packaging segment are concentrating around manufacturers who acquire rather than internally build connectivity capability, and the forecast reflects this acquisition-driven capability expansion as a distinct driver of competitive positioning in the fastest-growing packaging category. For instance, in April 2025, AptarGroup acquired Invetech's packaging division, adding smart packaging and connectivity technology for biologic products to its portfolio and extending its digital packaging capability into a device category that traditional sterile barrier packaging alone could not fully address. These are some of the key factors driving revenue growth of the market.

Because any new sterile barrier packaging design must complete extensive ISO 11607 validation testing, including accelerated aging and seal integrity studies, before a device manufacturer can commercialise it, packaging design changes carry a multi-month to multi-year validation timeline that slows adoption of new formats regardless of their functional or cost advantages.

Rising sustainability compliance costs across plastic packaging formats are a second constraint, because expanding extended producer responsibility regulation and recyclability requirements in major markets are raising compliance costs for conventional multi-layer plastic packaging formats, pushing manufacturers toward recyclable mono-material alternatives that themselves require separate sterile barrier validation.

Packaging supply chain concentration risk is a third constraint, since the largest sterile barrier packaging manufacturers serve a substantial share of global device OEM demand, and the pending combination of two of the industry's largest suppliers concentrates this supply base further, raising genuine questions among device OEMs about long-term supplier diversification.

These factors substantially limit medical device packaging market growth over the forecast period.

The clearest driver of demand is sterile barrier system demand, which tracks the underlying global medical device production volume directly, since every sterile, single-use device requires validated packaging to maintain sterility until point of use. A sterile barrier system's entire function is to preserve device sterility from manufacturing through clinical use, so this packaging category's demand is structurally tied to sterile device production volume rather than to any discretionary purchasing decision, making it one of the most demographically and clinically predictable packaging categories. Flexible packaging accounts for the largest single format category share, and Amcor's Medical Laminates solution, offering an entire packaging construction recyclable in the polyethylene stream, reflects continued innovation within this established, high-volume format category. The effect on the market is that baseline sterile barrier packaging demand remains structurally resilient, providing a stable revenue floor beneath the market's consolidation and smart packaging dynamics. These are some of the key factors driving revenue growth of the market.

The second driver is manufacturer consolidation combining plastics and packaging capacity, as the largest packaging companies pursue transactions that reshape the competitive landscape at a scale not previously seen in this market. A device OEM specifying packaging across a global product portfolio benefits from a supplier with the scale and manufacturing footprint to guarantee consistent supply across multiple regions, so consolidation that creates larger, more geographically comprehensive suppliers directly addresses a genuine device OEM supply chain resilience concern. In November 2024, Amcor announced its acquisition of Berry Global in an all-stock transaction valued at approximately USD 8.4 billion, creating a combined healthcare packaging entity with approximately USD 24 billion in combined annual revenues and targeted annual cost synergies of USD 650 million by the third year following close. The effect on the market is that device OEM packaging specification decisions increasingly weigh supplier scale and consolidated manufacturing footprint alongside material and format performance. These are some of the key factors driving revenue growth of the market.

The Amcor-Berry Global combination targets approximately USD 24 billion in combined annual revenue and USD 650 million in annual cost synergies within three years of closing. This is the largest structural consolidation this market has seen, reshaping device OEM supplier options at a scale not previously available.

The third driver is smart packaging technology extending connectivity and traceability capability into biologic and drug-device combination product packaging, a category traditional sterile barrier packaging alone cannot fully address. An increasing share of biologic and combination products benefit from packaging that supports usage tracking, cold-chain monitoring, or patient adherence features alongside traditional sterile barrier performance, so packaging manufacturers that acquire or develop connectivity technology can capture specification decisions for this higher-value, technology-differentiated product category. In April 2025, AptarGroup acquired Invetech's packaging division, adding smart packaging and connectivity technology for biologic products to its portfolio, extending digital packaging capability beyond conventional sterile barrier and dispensing formats. The effect on the market is that smart and connected packaging is becoming a distinct, faster-growing category within the broader packaging market, separate from conventional sterile barrier system revenue. These are some of the key factors driving revenue growth of the market.

However, the medical device packaging market faces severe adoption constraints from ISO 11607 sterile barrier validation timeline requirements and rising sustainability compliance costs across plastic packaging formats.

Because any new sterile barrier packaging design must complete extensive ISO 11607 validation testing, including accelerated aging and seal integrity studies, before a device manufacturer can commercialise it, packaging design changes, including AptarGroup's newly acquired smart packaging technology, carry a multi-month to multi-year validation timeline that slows adoption of new formats regardless of their functional or cost advantages.

Rising sustainability compliance costs across plastic packaging formats compound this, because expanding extended producer responsibility regulation and recyclability requirements in major markets are raising compliance costs for conventional multi-layer plastic packaging formats, pushing manufacturers toward recyclable mono-material alternatives such as Amcor's Medical Laminates that themselves require separate sterile barrier validation.

Packaging supply chain concentration risk is the third constraint, since the largest sterile barrier packaging manufacturers serve a substantial share of global device OEM demand, and the pending combination of Amcor and Berry Global concentrates this supply base further, raising genuine questions among device OEMs about long-term supplier diversification.

These factors substantially limit medical device packaging market growth over the forecast period.

Based on material, the global medical device packaging market is segmented into plastic and polymer films, glass, paper and paperboard, and metal and foil. Plastic and polymer films hold the largest revenue share, because polyethylene, polypropylene, PET, and nylon multi-layer laminates span the broadest range of sterile barrier and flexible packaging applications, which suits a market where multi-application versatility commands the largest revenue category. Glass remains essential for prefilled syringes, vials, and ampoules where drug-device combination product requirements demand it, anchored by Schott's and Gerresheimer's established glass manufacturing capacity. Metal and foil is expected to register a significant revenue growth rate in the global medical device packaging market over the forecast period, driven by expanding lidding film applications for rigid tray sterile barrier systems.

Based on packaging type, the global medical device packaging market is segmented into flexible, rigid, smart and connected, and secondary or tertiary packaging. Flexible packaging holds the largest revenue share, because pouches, lidding films, and sterile barrier bags represent the dominant format for the majority of sterile single-use device packaging, which ties directly back to the sterile barrier demand described in the market's primary demand driver. Smart and connected packaging is expected to register the fastest revenue growth rate in the global medical device packaging market over the forecast period, driven by AptarGroup's expanded Invetech-derived connectivity portfolio and comparable technology extending into biologic and combination product applications.

Sterile barrier systems product application is expected to account for the largest revenue share in the global medical device packaging market during the forecast period

Based on product, the global medical device packaging market is segmented into sterile barrier systems, surgical instrument packaging, drug-device combination packaging, diagnostic test kit packaging, and implant or orthopedic device packaging. Sterile barrier systems hold the largest revenue share, because ISO 11607-compliant pouches and trays are required across the broadest range of sterile single-use device categories, which ties directly back to the sterile barrier demand described in the market's primary demand driver. Drug-device combination packaging is expected to register the fastest revenue growth rate in the global medical device packaging market over the forecast period, driven by Schott's and Gerresheimer's continued collaboration on premium glass and polymer packaging for injectable medicines.

Based on regional analysis, the medical device packaging market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of medical device OEM headquarters and packaging manufacturer commercial activity creates the deepest specification demand globally, and because Amcor, West Pharmaceutical Services, and Sealed Air all maintain their primary commercial presence in the US market. BD's major contract win in May 2025 for end-to-end primary and secondary packaging for a leading pharmaceutical company's product portfolio specifically reinforces the depth of US packaging services demand. The concentration of FDA-regulated device manufacturing activity in the country also means new sterile barrier and smart packaging technologies are typically specified into US device designs first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, Switzerland, and Italy represent significant national markets within Europe, reinforced by Gerresheimer's and Schott's continued collaboration on premium glass and polymer packaging headquartered in the region. The result is steady rather than rapid growth, shaped more by EU MDR and sustainability compliance requirements than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and India represent two of the largest national markets within the region, driven by expanding medical device manufacturing capacity and rising sterile device production volume. The region's rapidly scaling contract device manufacturing base leaves considerably more room for growth than in the already packaging-specification-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with Gerresheimer's EUR 100 million Queretaro, Mexico facility, which commenced production in the second quarter of 2025, specifically expanding regional glass and polymer packaging manufacturing capacity. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised polymer resin and glass raw materials that Latin American packaging manufacturers depend on, an effect expected to run through 2026 and slow medical device packaging adoption beyond Brazil's and Mexico's main manufacturing centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding medical device manufacturing investment and the UAE's regional distribution hubs represent the primary investment centres for medical device packaging adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the sterile barrier packaging manufacturing infrastructure needed to support advanced specification at scale.